TY - JOUR
T1 - Platelet survival and function in animals with prosthetic mitral valve
T2 - The effect of nafazatrom
AU - Al-Mondhiry, H.
AU - Pierce, W. S.
AU - Richenbacher, W.
PY - 1984
Y1 - 1984
N2 - Thromboembolism remains a serious problem in patients with prosthetic heart valves. Previous studies documented a number of platelet abnormalities in such patients and correlated the occurrence of thromboembolic complications with short platelet survival. We have studied platelet survival and platelet aggregation in eight goats fitted with prosthetic mitral valves and repeated the studies following treatment with nafazatrom, a potent antithrombotic agent. Eleven survival studies in eight animals showed a platelet survival not significantly different from control (6.52 ± 0.72 vs. 6.94 ± 0.81 days). Following seven to ten days of oral drug administration, platelet survival in the test animals was 7.34 ± 0.96 days, significantly longer than pretreatment results (p < 0.01). Animals with the shortest pretreatment platelet survival achieved substantial prolongation of platelet life span following drug treatment. The drug caused no change in ex vivo platelet aggregation.
AB - Thromboembolism remains a serious problem in patients with prosthetic heart valves. Previous studies documented a number of platelet abnormalities in such patients and correlated the occurrence of thromboembolic complications with short platelet survival. We have studied platelet survival and platelet aggregation in eight goats fitted with prosthetic mitral valves and repeated the studies following treatment with nafazatrom, a potent antithrombotic agent. Eleven survival studies in eight animals showed a platelet survival not significantly different from control (6.52 ± 0.72 vs. 6.94 ± 0.81 days). Following seven to ten days of oral drug administration, platelet survival in the test animals was 7.34 ± 0.96 days, significantly longer than pretreatment results (p < 0.01). Animals with the shortest pretreatment platelet survival achieved substantial prolongation of platelet life span following drug treatment. The drug caused no change in ex vivo platelet aggregation.
UR - http://www.scopus.com/inward/record.url?scp=0021213539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021213539&partnerID=8YFLogxK
U2 - 10.1055/s-0038-1661148
DO - 10.1055/s-0038-1661148
M3 - Article
C2 - 6523440
AN - SCOPUS:0021213539
SN - 0340-6245
VL - 52
SP - 99
EP - 101
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 2
ER -